The company said improved preclinical models are required to develop and deploy targeted therapies to improve patients’ lives.

Patient-derived primary tumor cell models grown in 3D culture conditions coupled with molecular characterization offers a stronger correlation to clinical outcomes.

The next generation system could enable personalized cancer treatments as well as develop safer and/or more efficient anti-cancer drugs.